**12. Newer agents to ameliorate membrane damage**


*Preservation of Peritoneal Membrane Structure and Function in Peritoneal Dialysis DOI: http://dx.doi.org/10.5772/intechopen.111586*


The potential MMT modulators untested in PD are depicted in **Table 2**:

A study in a rat model, by using the stem cells demonstrated that the xenografts of human umbilical mesenchymal stem cells prevented the PD-induced membrane alterations [31].

By the advent of the proteomics and functional genomics analysis of the MC and the EMT, these fine biomarkers can be used for the accurate follow-up of the progressive peritoneal membrane deterioration. They also will identify the master molecules which governs the mesenchymal transition of MC. These molecular profiles of the EMT process in future might become an excellent tool to test the biocompatibility of newer PD fluids. Although further studies are needed, it is expected that increasing knowledge will provide a novel approach for therapeutic benefits in the treatment of peritoneal fibrosis, thus maintaining the peritoneal membrane for an extended period in PD patients.


#### **Table 2.**

*Potential MMT modulators untested IN PD.*
